Milan
,
Italy
28 September - 2 October 2026
The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026)
Interview with Professor Tina Vilsbøll, Senior Medical Officer, Novo Nordisk A/S
Medical Commentary: Draft ADA/EASD Consensus Report 2026
In this interview, Professor Tina Vilsbøll shares her clinical perspective on the draft ADA/EASD Consensus Report 2026, following its release for public comment at ADA 2026 and ahead of the final report at EASD 2026. She reflects on the growing role of GLP-1–based therapy, the shift from glucose-focused care to a broader view of the whole patient, and the increasing focus on comorbidities including cardiovascular, kidney and liver disease.
Presentation schedule and materials
Monday, 28 September 2026
09:00
- 16:30
CEST
Symposium
Advancing person-centred care across the cardiometabolic spectrum through scientific innovation
Anna Secher
;
Carel le Roux
;
Chantal Mathieu
;
Concetta Irace
;
Erin Bohula
;
Harpreet Bajaj
;
John Buse
;
Katherine Tuttle
;
Kirsi Pietiläinen
;
Martin Wabitsch
;
Pablo Mora
;
Philip Newsome
;
Roopa Mehta
;
Zoe Williams
MATERIALS AVAILABLE
12:00
- 13:00
CEST
LBA 44
SHORT ORAL PRESENTATION
Major Adverse Cardiovascular Events in Adults With Type 2 Diabetes Escalating to Semaglutide 2.0 mg vs Switching to Tirzepatide
Gang Fang1; Chalak Muhammad1; Caroline Swift1; Josh Noone1; Yuanjie Liang1; Sherif Mehanna1; Thomas P. Gunnarsson2; Kathryn Tierney3
MATERIALS AVAILABLE
Tuesday, 29 September 2026
13:15
- 14:15
CEST
828
POSTER
Achievement of HbA1c, body weight loss, and hypoglycaemia composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D: post-hoc analysis from SUSTAIN FORTE
Harpreet S. Bajaj1; Chethana KR2; Thomas P. Gunnarsson3; Suvanjaa Sivalingam3; Nikolaos Tentolouris4; John Buse5
MATERIALS AVAILABLE
13:15
- 14:15
CEST
829
POSTER
Efficacy of subcutaneous once-weekly semaglutide in recently diagnosed type 2 diabetes participants: An individual-level, pooled analysis of SUSTAIN trials
Concetta Irace1; Anna Areovimata2; Filipe Cortes-Figueiredo2; Bharath Kumar3; Nikolaos Tentolouris4
MATERIALS AVAILABLE
13:15
- 14:15
CEST
824
POSTER
Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: Predicting weight reduction and gastrointestinal tolerability
Rune Viig Overgaard1; Mathilde Guldbæk Arentsen1; Andrei-Mircea Catarig1; Filipe Cortes-Figueiredo1; Paula Freitas2; Jan-Otto Hooghoudt1; Anders Strathe1; Minh Chau Tran1; Nikolaos Tentolouris3
MATERIALS AVAILABLE
13:15
- 13:19
CEST
ORAL PRESENTATION
Impact of cagrilintide 2.4 mg on physical function – post hoc patient-reported outcomes from REDEFINE 1
D. Rubino1; R.M. Abschneider2; M. Blüher3; S.M. Bernt Jørgensen2; R.L. Kolotkin4,5; D. Li2; K.H. Pietiläinen6; M. Ried-Larsen2, T. Wadden7
MATERIALS AVAILABLE
14:45
- 16:15
CEST
LBA 11
ORAL PRESENTATION
Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1
Richard E. Pratley1; Rajdeep Adhya2; Anna Casu1; W. Timothy Garvey3; Joran Hjelmesæth4; Lars Johansson5; Alex Videmark6; Torquil Watt6; Vanita R. Aroda7
MATERIALS AVAILABLE
14:45
- 16:15
CEST
LBA 12
SHORT ORAL PRESENTATION
Effect of CagriSema on achievement of composite HbA1c and body weight reduction targets in participants with type 2 diabetes: REIMAGINE 1
A. B. Jain1,2; J. Aberle3; R. Adhya4; L. K. Billings5; R. Gajria6; T. Watt6; R. Pop-Busui7
MATERIALS AVAILABLE
14:45
- 16:15
CEST
826
SHORT ORAL PRESENTATION
Blood pressure changes with once-weekly semaglutide 7.2 mg in adults with obesity: post hoc analysis of the STEP UP randomised, controlled trial
Jøran Hjelmesæth1,2;
Paula Freitas3,4;
Christine Sofie Fuchs Jacobsen5; Hanna Angelene
Kudiyanur Muniraju6; Signe
Stensen5; W. Timothy
Garvey7
MATERIALS AVAILABLE
16:15
- 16:45
CEST
Symposium
Essence of MASH management: practical strategies to improve patient outcomes in diabetes clinics
Alice Cheng
;
Philip Newsome
MATERIALS AVAILABLE
18:00
- 19:30
CEST
Symposium
Semaglutide in obesity care: comprehensive evidence and emerging science
Jaime Almandoz
;
Sean Wharton
;
Barbara McGowan
;
Liana Billings
MATERIALS AVAILABLE
Wednesday, 30 September 2026
11:45
- 12:45
CEST
SO 039
POSTER
Improvements in liver histology and non-invasive tests are independent of baseline BMI in participants with obesity and MASH: A post hoc analysis from the ESSENCE trial
M. Roden1, M.T. Arias-Loste2, E. Bugianesi3, L. Castera4, N.M. Eklöf5, W. Kim6, N. Krarup5, B. Ludvik7, P.N. Newsome8, V. Ratziu9, A.J. Sanyal10, A. Trifan11, T.C. Vestergaard5, M.E. Rinella12, on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
11:45
- 12:45
CEST
LBA 86
ORAL PRESENTATION
Effect of CagriSema on continuous glucose monitoring in people with inadequately controlled type 2 diabetes: REIMAGINE 2
Julia K. Mader1; John B. Buse2; Helene H. Hansen Duus3; Therese Wilbek Fabricius3; Chantal Mathieu4; Alex Videmark3; Harpreet S. Bajaj5
MATERIALS AVAILABLE
11:45
- 12:45
CEST
LBA 85
ORAL PRESENTATION
Effect of CagriSema on bone biomarkers in participants with inadequately controlled type 2 diabetes: REIMAGINE 2
Martin Haluzík1; Therese Wilbek Fabricius2; Reena Gajria2; Sathish Manogaran3; Marco Ponzetti2; João Eurico Fonseca4
MATERIALS AVAILABLE
11:45
- 12:45
CEST
SO 039
POSTER
HbA1c-independent benefits of semaglutide on liver histology and non-invasive tests in participants with biopsy-defined MASH: insights from post hoc analysis of the ESSENCE trial part 1
P.N. Newsome1, A.J. Sanyal2, E. Bugianesi3, M.T. Arias-Loste4, L. Castera5, N.M. Eklöf6, W. Kim7, N. Krarup6, B. Ludvik8, V. Ratziu9, M.E. Rinella10, A. Trifan11, T.C. Vestergaard6, M. Roden12, on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
11:45
- 12:45
CEST
SO 039
POSTER
Longitudinal dynamics of cardiometabolic parameters in a MASH population stratified by baseline glycemia and treated with semaglutide: post hoc insights from the ESSENCE trial part 1
M. Roden1, M.T. Arias-Loste2, E. Bugianesi3, L. Castera4, N.M. Eklöf5, W. Kim6, N. Krarup5, B. Ludvik7, P.N. Newsome8, V. Ratziu9, A.J. Sanyal10, A. Trifan11, T.C. Vestergaard5, M.E. Rinella12, on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
11:45
- 12:45
CEST
LBA 59
SHORT ORAL PRESENTATION
3-Month Real-World Weight Outcomes Among Patients With Overweight or Obesity After Switching From Injectable Semaglutide or Tirzepatide to Oral Semaglutide for Weight Management: The OCTANE Study
B.J. Smith1;V. Divino2; C.S. Morgen3; L. Broffman1; L. Wilson2; J. Bhavsar2; R. Manalac1; R. Patel2; S. Chai1; L.J. Aronne4; B.G. Tchang4
MATERIALS AVAILABLE
13:00
- 14:00
CEST
708
POSTER
The effects of semaglutide on health-related quality of life in adults with type 2 diabetes and chronic kidney disease: FLOW trial
Johannes Mann1,2; Ida Kirstine Bull Rasmussen3; Thomas P Gunnarsson3; Prachi Priyadarshini4; Søren Rasmussen3; Peter Rossing5
MATERIALS AVAILABLE
14:30
- 16:00
CEST
POSTER
UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial
Zhiguang Zhou1; Dexue Liu2; Jiao Sun3; Sihong Wang4; Hongyan Shu5; Wenli Sun6; Haifang Wang7; Li Cong8; Li Mao9; Liujun Fu10; Shenglian Gan11; Lili Zhang12; Huiru Yan13; Nicolas Belmar14; Haiyan Zhang13
MATERIALS AVAILABLE
14:30
- 16:00
CEST
122
POSTER
Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity
Valdemar Funch Uhre1; Merita Alex2; Nikolaj Bak1; Christa Broholm1; Søren A. Fuglsang1; Anthony P. Goldstone3; Christian Keicher4; Alice Motovylyak5; Kirsi H. Pietiläinen6; Claire Prener Miller1; Roni Setton7; Elif Sikoglu5; Janne R. Hingst1
MATERIALS AVAILABLE
16:30
- 17:30
CEST
S21
SHORT ORAL PRESENTATION
REIMAGINE 1, 2 and 3 – trial designs, key results and clinical perspectives
Vanita R. Aroda1
MATERIALS AVAILABLE
Coming soon
17:45
- 19:15
CEST
Symposium
Advancing the amylin story: from scientific rationale to future cardiometabolic care
Carel le Roux
;
Thomas Lutz
;
Arya M. Sharma
;
Akshay Jain
;
Vanita Aroda
MATERIALS AVAILABLE
Thursday, 01 October 2026
12:15
- 12:45
CEST
Symposium
Let’s talk amylin: the next wave in metabolic and obesity care
W. Timothy Garvey
;
Akshay Jain
;
Liana Billings
MATERIALS AVAILABLE
12:45
- 13:45
CEST
SO 035
POSTER
Semaglutide provides liver health-related benefits in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1
L.L. Gluud1, M.F. Abdelmalek2, M.T. Arias-Loste3, B. Demirel4, G. Frühbeck5, A. Geerts6, L. Ladrón de Guevara7, E. Janczewska8, O.K. Jeppesen4, C. Oliveira9, M.E. Rinella10, G. Sebastiani11, A. Trifan12, T.C. Vestergaard4, E. Bugianesi13
MATERIALS AVAILABLE
12:45
- 13:45
CEST
SO 035
POSTER
Semaglutide improves cardiometabolic risk factors in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1
L.L. Gluud1, M.F. Abdelmalek2, M.T. Arias-Loste3, B. Demirel4, G. Frühbeck5, A. Geerts6, L. Ladrón de Guevara7, E. Janczewska8, O.K. Jeppesen4, C. Oliveira9, M.E. Rinella10, G. Sebastiani11, A. Trifan12, T.C. Vestergaard4, E. Bugianesi13
MATERIALS AVAILABLE
12:45
- 12:49
CEST
529
SHORT ORAL PRESENTATION
Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP trials
Eric Lawitz1; W. Timothy Garvey2; Christine Sofie Fuchs Jacobsen3; María Quiroga3; Lauren Wilson4; Philip N. Newsome5
MATERIALS AVAILABLE
12:45
- 13:45
CEST
854
POSTER
Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline BMI: COMBINE 4
Linong Ji1; Raluca Maltesen2; Laura Pletsch-Borba3; Cathrine Scavenius3; Daisuke Yabe4; Viswanathan Mohan5
MATERIALS AVAILABLE
12:45
- 13:45
CEST
853
POSTER
Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline HbA1c: COMBINE 4
Viswanthan Mohan1; Linong Ji2; Raluca Maltesen3; Laura Pletsch-Borba4; Cathrine Scavenius4; Daisuke Yabe5
MATERIALS AVAILABLE
12:45
- 13:45
CEST
853
POSTER
Effects of semaglutide on patient-reported outcomes in individuals with peripheral artery disease and type 2 diabetes: Findings from the STRIDE trial
Harald Sourij1; Andrei-Mircea Catarig2; Rajitha K3; Dainis Krievins4; Bernhard Ludvik5; Kevin Mani6; Joakim Nordanstig7; Sanjana Prabhu3; Neda Rasouli8; Subodh Verma9; Marc P Bonaca10
MATERIALS AVAILABLE
12:45
- 12:49
CEST
592
ORAL PRESENTATION
Relationship between mean CagriSema dose and weight loss in the REDEFINE 1 trial
W. Timothy Garvey1; Jaime Almandoz2; Mikkel Hovden Christensen3; Cynthia Karenina Osorto Contreras3; Anthony N. Fabricatore4; Thomas Bo Jensen3; Michael G. Knight5, Kirsi H. Pietiläinen6,7; Carel W. le Roux8,9
MATERIALS AVAILABLE
12:45
- 13:45
CEST
339
SHORT ORAL PRESENTATION
Are people living with type 2 diabetes in the UK reaching guideline-recommended treatment targets two years after diagnosis?
Kevin Fernando1,2; Tariq Halasa3; Fan Liu3; Amine Lotfi3; Torquil Watt3; Eva Johnsen3
MATERIALS AVAILABLE
14:00
- 15:00
CEST
815
POSTER
Semaglutide treatment patterns in treatment-naive individuals with type 2 diabetes: insights from Danish registry data
Andreas Andersen1; Jessica Bengtsson2; Anders Boeck Jensen2; Anusha Jahagirdar3; Christina Louise Rasmussen2; Araz Rawshani4
MATERIALS AVAILABLE
14:00
- 15:00
CEST
814
POSTER
Effects of once-weekly semaglutide treatment on HbA1c and body weight in people with recently diagnosed type 2 diabetes: a non-interventional, comparative effectiveness study
Rasouli N1; Jensen AB2; Bengtsson J2; Cortes-Figueiredo F2; Deinega A2; Kushner P3
MATERIALS AVAILABLE
14:00
- 15:00
CEST
860
POSTER
Continuous glucose monitoring-based metrics in adults switching to once-weekly icodec without an initial one-time additional dose vs once-daily glargine U100: Post hoc analysis of ONWARDS 10
Chantal Mathieu1; Alexander Abitbol2; Gayathri Anil3; Jonas K. Lindeløv4; Laura Pletsch-Borba4; Richard M. Bergenstal5
MATERIALS AVAILABLE
18:45
- 20:15
CEST
Symposium
Changing the trajectory of chronic metabolic disease: the evolving role of GLP-1-based care
Alice Cheng
;
Kirsi Pietiläinen
;
Eric Lawitz
;
Katherine Tuttle
MATERIALS AVAILABLE
Friday, 02 October 2026
11:30
- 12:30
CEST
250
ORAL PRESENTATION
Spatiocellular mapping indicates complementary action of amylin and GLP1 receptor agonism in the human brain
Sofia Lundh1; Mette Ludwig1; Sarah Bau1; Georgina Dowsett2; Lukas Steuernagel2; Jens Brüning2;Giles Yeo3; Anna Secher1; Kirsten Raun1
MATERIALS AVAILABLE
Keywords